Vnitr Lek 2022, 68(7):454-457 | DOI: 10.36290/vnl.2022.095

Effect of SGLT2 inhibitor empagliflozin on the stabilization of heart failure progress with the possibility of further interventions in a patient with HFrEF - a case report

Filip Málek
Kardiovaskulární centrum, Nemocnice Na Homolce, Praha

SGLT2 inhibitors are included in the first line medical therapy of HFrEF. We report a case study of a patient in whom introduction of treatment with empagliflozin after recurrent heart failure decompensation lead to stabilization of the progress of the disease. Heart failure progress stabilization enabled interventions of cardiovascular comorbidities with delay of heart transplantation or mechanical assist device implantation need.

Keywords: empagliflozin, heart failure progress, stabilization.

Accepted: October 17, 2022; Published: October 31, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Málek F. Effect of SGLT2 inhibitor empagliflozin on the stabilization of heart failure progress with the possibility of further interventions in a patient with HFrEF - a case report. Vnitr Lek. 2022;68(7):454-457. doi: 10.36290/vnl.2022.095.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Packer M, Anker SD, Butler J et al. For the EMPEROR‑Reduced Trial Investigators Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureN Engl J Med 2020 383,15:1413-24
    2. Mc Donagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021; doi:10.1093/eurheartj/ehab368 Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.